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Abbreviations:  52 
IBD  inflammatory bowel disease 53 
WSAVA world small animal veterinary association 54 
GI  gastrointestinal  55 
cPLI   pancreatic-lipase immunoreactivity  56 
cTLI  trypsin-like immunoreactivity  57 
H&E  hematoxylin and eosin 58 
CIBDAI canine IBD activity index 59 
CCECAI canine chronic enteropathy activity index 60 
LP  lamina propria 61 
CI  confidence interval 62 
GC  granulomatous colitis 63 
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ABSTRACT 78 
Prior studies have failed to detect a convincing association between histologic lesions of 79 
inflammation and clinical disease activity in dogs with inflammatory bowel disease (IBD). We 80 
hypothesized that use of a simplified histopathologic scoring system would improve the 81 
consistency of interpretation among pathologists when describing histologic lesions of 82 
gastrointestinal inflammation. Our aim was to evaluate the correlation of histopathologic changes 83 
to clinical disease activity in dogs with IBD using this new system. Forty two dogs with IBD and 84 
19 healthy control dogs were enrolled in this retrospective study. Endoscopic biopsies from the 85 
stomach, duodenum, ileum, and colon were independently scored by 8 pathologists. Clinical 86 
disease activity was scored using the canine inflammatory bowel disease activity index (CIBDAI) 87 
or the canine chronic enteropathy clinical activity index (CCECAI), depending on the individual 88 
study center (USA vs. UK, respectively). Summative histopathological scores and clinical disease 89 
activity were calculated for each tissue (stomach, duodenum, ileum, and colon) and each tissue 90 
histologic score (inflammatory/morphologic feature). The correlation between CCECAI/CIBDAI 91 
and summative histopathologic score was significant (p<0.05) for duodenum (r = 0.42) and colon 92 
(r = 0.33). In evaluating the relationship between histopathologic scores and clinical disease 93 
activity, significant (p<0.05) correlations were observed for crypt dilation (r = 0.42), lamina propria 94 
(LP) lymphocytes (r = 0.40), LP neutrophils (r = 0.45), mucosal fibrosis (r = 0.47), lacteal dilation 95 
(r = 0.39), and villus stunting (r = 0.43). Compared to earlier grading schemes, the simplified 96 
scoring system shows improved utility in correlating histopathologic features (both summative 97 
histology scores and select histologic scores) to IBD clinical activity, at diagnosis, as defined by 98 
CIBDAI/CCECAI. 99 
 100 
 101 
  102 
 103 
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 Diagnosis of canine idiopathic inflammatory bowel disease (IBD) requires histopathologic 104 
confirmation of inflammation in intestinal biopsies.12,16,17,26,33,40  Previous studies have found it 105 
difficult to correlate histopathologic findings with clinical disease activity due to a lack of 106 
agreement among pathologists when describing histopathologic changes37 and inconsistent 107 
grading schemes reported by different groups2,3,6,7,9,10,15-18,24,26,29,32,35,40  investigating canine and 108 
feline chronic enteropathies. The World Small Animal Veterinary Association (WSAVA)* GI 109 
standardization grading scheme5 was an attempt to rectify some of these problems but even this 110 
was associated with poor agreement among pathologists39 .  111 
 Prior studies have failed to detect a convincing association of mucosal histopathology with 112 
clinical signs, biomarkers of inflammation, or response to therapy and outcome in dogs with IBD. 113 
2,4,9,13,21,22,27,29,32,41 One explanation for these findings is that histopathology and clinical activity are 114 
not associated; whereas, another possibility is that current WSAVA guidelines require refinement 115 
to improve diagnostic consistency.36 Recently, use of a simplified histopathologic scoring system 116 
has shown excellent agreement among pathologists in defining duodenal inflammation in dogs 117 
with IBD.14  118 
 We hypothesized that use of the simplified histopathologic scoring system will improve the 119 
consistency of interpretation among pathologists when evaluating gastric, duodenal, ileal, and 120 
colonic endoscopic biopsies. The aim of the present study was to evaluate the correlation of 121 
histopathologic changes to clinical disease activity in dogs with IBD using this new system. 122 
 123 
METHODS 124 
Ethical animal use 125 
 The collection and analysis of intestinal biopsies obtained endoscopically from healthy 126 
dogs and dogs with IBD were previously approved by the University of Giessen and the Iowa 127 
State University Institutional Animal Care and Use Committee. Written informed consent was 128 
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obtained from all owners of dogs enrolled in separate trials (University of Giessen: V54-19c 20 15 129 
(1) GI 18/17 Nr. 36/2011; ISU IACUC Log numbers: 1-11-7061-K, 12-11-7269-K). 130 
 131 
Animals 132 
 Two groups of dogs were studied. Group 1 comprised a cohort of 42 dogs diagnosed with 133 
idiopathic IBD according to previously published criteria.2,12,16,33 Dogs with IBD were enrolled from 134 
two study centers: the Royal Veterinary College (Allenspach) and Iowa State University (Jergens) 135 
from January 2010 to May 2012. Over this 2.5 year period, approximately 150 dogs at ISU and 300 136 
dogs at the RVC were referred for diagnostic evaluation of chronic gastrointestinal signs. In many instances, 137 
individual dogs underwent upper, lower, or both upper and lower GI endoscopy with collection of mucosal 138 
biopsies as part of the diagnostic investigation for their chronic GI signs. The inclusion criteria included 139 
persistent (> 3 weeks duration) GI signs, failure to respond to appropriate dietary trials (elimination 140 
diet fed exclusively for at least 3 weeks) and antimicrobial therapy (metronidazole or tylosin 141 
administered exclusively for 14 days or more), failure to document other causes for gastroenteritis 142 
by thorough diagnostic testing, and histopathologic evidence of mucosal inflammation in biopsy 143 
specimens.  144 
 The diagnostic evaluation in all dogs with IBD dogs consisted of extensive medical 145 
histories taken over one or more clinical examinations, hematological and serum biochemistry 146 
analyses, urinalysis, fecal examinations for parasites, diagnostic imaging ( abdominal radiographs 147 
in all and abdominal sonography performed in 31/42 dogs), and histopathologic examination of 148 
GI mucosal biopsy specimens. In some dogs, samples were additionally collected for a 149 
measurement of serum pancreatic-lipase immunoreactivity (cPLI), trypsin-like immunoreactivity 150 
(cTLI), cobalamin, and/or folate concentrations.  151 
 Group 2 dogs served as controls and were comprised of 19 young (<2 years old) healthy 152 
laboratory-reared beagles (n=12) and beagle cross mongrels (n=7). Each of these dogs was free 153 
of GI signs over several months preceding diagnostic evaluation. Moreover, control dogs were 154 
7 
 
 
 
judged to be healthy on the basis of normal results on physical examination, hematological and 155 
serum biochemical analysis, urinalysis, multiple fecal examinations, and Dirofilaria antigen assay. 156 
Mucosal biopsies of the small and large intestines were obtained from each dog as previously 157 
described2,16,33. 158 
 159 
Simplified histopathologic scoring system for gastrointestinal inflammation14 160 
 The simplified histopathologic scoring system for GI inflammation in dogs was based on 161 
the morphologic and inflammatory features contained in the original WSAVA GI standardization 162 
data set graded by the 4 individual pathologists who participated in that study. In brief, Chi-square 163 
analysis of these data was performed and compared the extent of agreement among study 164 
pathologists for each inflammatory and morphologic feature. The resultant P-values were then 165 
used to determine the inter-observer agreement among study pathologists for each single 166 
inflammatory or morphologic feature. The 3-5 histopathologic features that showed the least inter-167 
observer variability (based on Chi-square analyses) for GI inflammation involving the stomach, 168 
small intestine, and colon comprised the simplified scoring system.  169 
 The current study independently validates use of the simplified scoring system first tested 170 
on the original WSAVA study population. We now report use of this same system in a separate 171 
study population with tissues graded by a different group of pathologists. This allowed for 172 
quantification of parameters resulting in the derivation of summative histopathologic scores 173 
and individual histopathologic scores which could then be correlated to clinical disease activity 174 
in dogs with IBD. 175 
 176 
Histopathologic assessment 177 
 Hematoxylin and eosin (HE) stained tissue sections of formalin-fixed, paraffin-embedded 178 
endoscopic biopsies from the stomach, duodenum, ileum, and/or colon of each dog were 179 
evaluated for histologic lesions using a simplified scoring system for defining GI histopathological 180 
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changes. Only tissue sections of adequate diagnostic quality were used in the study.38 Poor 181 
quality tissues (those graded as marginal or inadequate) were excluded. Individual glass slides 182 
from the different regions of the GI tract of healthy and diseased dogs were scanned on-site using 183 
an Aperio digital pathology whole slide scanning system housed at Texas A&M University. Digital 184 
tissue images were then sent to each pathologist separately for review. Pathologists were blinded 185 
to the dogs’ status as a control dog or IBD patient. Up to five morphologic/inflammatory features 186 
in randomly sorted, HE-stained digital slides from each area of the GI tract were independently 187 
scored by the 8 study pathologists (Table 1). Individual pathologists’ lesion scores for each 188 
parameter were graded using a 4-point scale (i.e., 0 = normal, 1 = mild, 2 = moderate, 3 = marked 189 
histopathologic change). This resulted in the generation of both region-specific scores and 190 
summative histopathologic scores used for statistical analysis. The same histopathologic grading 191 
criteria used for duodenal biopsy specimens were used for diagnostic interpretation of ileal tissue 192 
specimens.  193 
  194 
Clinical disease activity 195 
 Severity of clinical disease (activity) at diagnosis was scored using either the canine 196 
chronic enteropathy clinical activity index (CCECAI)2 or the canine IBD activity index (CIBDAI)18 197 
at the different clinical trial centers.  198 
 199 
Statistical methods 200 
Correlations between histopathologic variable(s) and clinical disease activity were calculated for 201 
both cohorts. For each dog, the average summative histopathologic score in each area of the GI 202 
tract (i.e., averaged over the 3-5 histopathologic parameters) and individual histopathologic 203 
scores at each tissue location (stomach, duodenum, ileum and colon) were calculated for 204 
correlation to clinical activity indices. Pearson’s correlation coefficients between histopathological 205 
scores and clinical disease activity were calculated for each tissue location, and combination of 206 
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tissue and histologic score. Significance of the correlation was determined by Fisher Z- 207 
transformation tests using PROC CORR in SAS version 9.4. Prior to this, differences among 208 
pathologists on those correlations were evaluated using F-tests, after verifying the model 209 
assumptions of independence, homoscedasticity, and normality. For all tests, p-values < 0.05 210 
were considered statistically significant. 211 
 212 
Inter-observer agreement among pathologists by histopathologic variable 213 
 When no significant differences in the (histopathological/clinical) correlations were found 214 
among pathologists, Cohen’s  statistics were used to assess the extent of agreement among 215 
individual raters for each histopathologic variable.31 This was performed using a binary or 2-point 216 
scale (i.e., normal/mild and moderate/severe) as previously described.39 The resulting  statistic 217 
was interpreted as <0 less than chance agreement; 0.01-0.20 slight agreement; 0.21-0.40 fair 218 
agreement; 0.41-0.60 moderate agreement; 0.61-0.80 substantial agreement; 0.81-0.99 almost 219 
perfect agreement. This output generated both kappa statistics and p-values to assess the 220 
significance of the kappa scores. 221 
  222 
RESULTS 223 
  Of the 42 dogs with IBD assessed for clinical disease severity, 25 were enrolled at 224 
the RVC and scored using CCECAI while 17 were enrolled at ISU and scored using CIBDAI. 225 
For the RVC cohort, 11 dogs had mild clinical activity, 8 dogs had moderate clinical activity, 226 
and 6 dogs had severe clinical disease. For the ISU cohort, 2 dogs had mild clinical activity, 227 
7 dogs had moderate clinical activity, and 8 dogs had severe clinical disease. Overall, 14 of 228 
42 (33%) dogs with IBD had severe clinical disease (i.e., CIBDAI/CCECAI score >9) with 7/42 229 
(17%) dogs having hypoalbuminemia and/or ascites at IBD diagnosis. Thus, overall, 35/42 230 
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(83%) of study dogs had identical CIBDAI and CCECAI scores for correlation to 231 
histopathologic indices. 232 
 The areas of the GI tract available for diagnostic evaluation in the two dog groups are 233 
presented in Table 2. The collection of endoscopic biopsies from dogs with IBD was guided by 234 
localization of the predominant GI signs to the small intestine (enteritis, n = 8 dogs), large intestine 235 
(colitis, n = 4 dogs), or both small and large intestines (enterocolitis, n = 30 dogs). Digital images 236 
contained 6-15 individual endoscopic tissue specimens per glass slide depending on the area 237 
sampled. For some dogs, tissue samples from all four areas of the GI tract were not obtained due 238 
to anesthetic complications and time constraints, difficulty with endoscopic examination 239 
(retrograde ileoscopy), and/or clinical disease localization to a single area of the GI tract (e.g., 240 
signs of colitis alone).  241 
 Results of the F-test comparing the histopathological/clinical correlations among the 8 242 
pathologists did not show any significant differences when averaging summative histopathologic 243 
scores for the stomach, duodenum, ileum, or colon. Moreover, there was no significant difference 244 
among pathologists in the correlation of individual histopathological scores at each GI location 245 
and the clinical activity indices. In this instance, the histopathologic scores from all 8 pathologists 246 
were pooled together to calculate Pearson’s correlation coefficients and increase the power of 247 
the study for detection of statistically significant differences between histopathologic changes 248 
assigned by the 8 pathologists. 249 
 The correlation between CCECAI/CIBDAI and the summative histology score was 250 
significant (p<0.05) for duodenum (r = 0.42, 95% CI = [0.08-0.65]) and colon (r = 0.33, 95% CI = 251 
[0.04-0.57]). The correlation was nearly significant for ileum (p=0.06, r = 0.29, 95% CI = [-0.02-252 
0.55]) but non-significant for stomach (p=0.7, r = 0.05, 95% CI = [-0.24-0.34]). Evaluation of 253 
individual histopathologic scores showed numerous significant correlations between histology 254 
and clinical disease activity for all areas of the GI tract, and in particular, the duodenum, ileum 255 
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and colon (Table 3). These lesions encompassed a variety of morphologic and inflammatory 256 
changes including mucosal fibrosis, villus stunting, and crypt dilation, as well as changes in the 257 
character of the mucosal cellular infiltrate in dogs with IBD (Figure 1).  258 
 The kappa agreement among pathologists for histopathologic scores varied across 259 
regions of the GI tract (Table 4). The best agreement for lesions was seen for colonic scores and 260 
lamina propria (LP) eosinophils across 3 of 4 areas of the GI tract. Those histopathologic lesions 261 
having at least fair-to-moderate agreement (>0.21-0.40) based on  statistics included: stomach 262 
(fibrosis, LP lymphocytes/plasma cells, LP eosinophils); duodenum (villus stunting, crypt dilation, 263 
lacteal dilation, LP lymphocytes/plasma cells, LP eosinophils); and colon (crypt dilation, LP 264 
eosinophils and macrophages). 265 
 266 
DISCUSSION 267 
 Characterizing the extent and severity of GI inflammation in endoscopic biopsy specimens 268 
from dogs and cats is difficult. Several studies from different institutions have shown that a variety 269 
of factors influence histopathologic interpretation of intestinal biopsies including (1) the correct 270 
area of the GI tract to be sampled36, (2) the number and quality of tissue samples submitted to 271 
the laboratory38, (3) the quality of sample processing by the laboratory39, and (4) the lack of 272 
consistency in interpretation of histopathologic changes among pathologists5,37. Complicating 273 
these potential limitations are various grading schemes for interpretation of intestinal 274 
histopathology which have failed to gain uniform acceptance in different laboratories. In response 275 
to these concerns, the WSAVA GI Standardization Group designed a histopathologic template for 276 
characterizing the nature and severity of mucosal inflammatory and morphologic changes. It was 277 
hoped that this might reduce variation among different pathologists and different institutions.5 278 
 Unfortunately, significant inter-observer variability in the diagnostic interpretation of 279 
endoscopic mucosal specimens exists even with the use of the original WSAVA standardization 280 
criteria.36,39 Moreover, the original WSAVA criteria do not consider some parameters, such as 281 
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changes in the number of colonic goblet cells and their content of mucus, although this parameter 282 
may be decreased in granulomatous colitis (GC) and other forms of colitis28,30, and may be 283 
significantly increased post-treatment20. A recent study evaluated a simplified histopathologic 284 
scoring system using select WSAVA template criteria (i.e., those indices having the greatest 285 
agreement among WSAVA pathologists) to reduce variability in the diagnostic interpretation of GI 286 
inflammation among pathologists.14 However, this investigation only graded inflammation in 287 
canine duodenal endoscopic biopsies and, like the original WSAVA study, did not include 288 
evaluation of ileal biopsy specimens.  289 
 The present study aimed to build on earlier observations using the simplified 290 
histopathologic scoring system, now extending its use to other areas of the GI tract (stomach, 291 
ileum, and colon) and correlating quantifiable histopathologic changes to clinical disease activity 292 
in dogs with IBD. Numerous studies from different groups have failed to show a consistent 293 
association between mucosal histopathologic changes and clinical disease severity; either at 294 
diagnosis or in response to different treatments. Jergens et al18 showed that clinical scores 295 
(CIBDAI) correlated best to a combination of histopathologic inflammation and serum C-reactive 296 
protein at IBD diagnosis; post-treatment histopathologic assessment was not performed in these 297 
dogs. In another study, clinical signs (CIBDAI scores) improved with medical treatment in dogs 298 
with IBD, but this did not result in significant changes in the severity of gastric or duodenal 299 
histologic inflammatory lesions.9 In separate studies, Allenspach et al showed that total 300 
lymphocyte numbers in the duodenal mucosa of dogs with IBD did not change in response to 301 
successful cyclosporine treatment1, and that histopathologic scores were not correlated with 302 
CCECAI scores, endoscopy scoring, or long-term outcome in dogs with IBD over 3 years2. In 303 
this latter paper (Allenspach), the presence of severe mucosal lesions in the duodenum 304 
(observed during duodenoscopy), hypoalbuminemia, and low serum cobalamin were 305 
significantly associated with negative outcome in dogs with chronic enteropathy. Munster et al22 306 
failed to demonstrate a strong correlation between treatment response (CIBDAI) and severity of 307 
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histopathologic lesions of IBD. Finally, Rossi et al25 showed reduced histopathologic lesion 308 
scores, accompanied by a positive clinical response (CIBDAI), following an 8-week course of 309 
combination probiotic therapy, while White et al34 did not despite using the same probiotic 310 
protocol. Difficulties in showing associations in these earlier studies may relate to the use of 311 
non-standardized histopathologic scoring systems and/or differences in study design.  312 
 Use of the simplified scoring system was repeatable among the different 313 
pathologists in the current study. The results comparing histopathological/c linical 314 
correlations among pathologists did not show significant differences when averaging 315 
summative histopathologic scores for the stomach, duodenum, ileum or colon. 316 
Moreover, there was no significant difference among pathologists in the correlation 317 
of individual histopathological scores within separate areas of the GI tract and 318 
clinical disease activity. These findings suggest that histologic scores of mucosal 319 
inflammation and morphologic change can be consistently applied to the scoring 320 
system. 321 
We also observed significant correlations between some histologic scores and 322 
clinical indices. Clinical activity in dogs with IBD was positively correlated to the 323 
summative histopathologic scores for the duodenum and colon. While the correlation 324 
between clinical disease and the summative histopathologic score approached 325 
significance (p = 0.06) for ileal biopsies, it was clearly not significantly correlated 326 
for the stomach. The association between histologic scores and clinical severity 327 
scored by internists was also significantly positive for several mucosal 328 
inflammatory/morphologic changes, including increased numbers of LP lymphocytes 329 
and neutrophils (duodenum), mucosal fibrosis (stomach and colon), crypt dilation 330 
(ileum and colon), and villus stunting (duodenum and ileum). 331 
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 The histologic score of gastric fibrosis was correlated with clinical disease activity in our 332 
dogs with IBD. This was an interesting observation considering that the total gastric 333 
histopathology score was not correlated to disease activity in affected dogs. In the original 334 
WSAVA study, gastric fibrosis was combined with other morphologic changes indicative of 335 
mucosal injury (including glandular nesting and mucosal atrophy) to define the presence and 336 
extent of gastric inflammation.5  The system used to grade gastritis in the present study (the 337 
simplified scoring system) was adapted from that proposed by the WSAVA standardization group 338 
and also included gastric fibrosis/mucosal atrophy as one parameter of morphologic injury. One 339 
standardized photographic grading scheme for evaluating gastric atrophy, fibrosis, and cellular 340 
infiltrates has also been proposed for characterizing gastritis in dogs.11 In this previous study, 341 
expression of IL-1 and the presence of mast cells and atrophy were related to gastric fibrosis. 342 
While the association of cytokines and cellular infiltrates with architectural changes was not 343 
investigated in the present study, it is possible that IL-1 and other inflammatory mediators in the 344 
lesions of IBD were related to gastric fibrosis.8,19,23 345 
 There was no correlation between the numbers of colonic goblet cells, intra-epithelial 346 
lymphocytes, LP eosinophils, and macrophages with IBD clinical disease activity. Changes in the 347 
numbers of goblet cells in dogs with colitis have been previously described in separate clinical 348 
studies. Roth et al26, using a colitis score comprised of LP cellular infiltrates, epithelial architecture, 349 
intra-epithelial lymphocytes, and number of goblet cells, showed that dogs with moderate-to-350 
severe IBD colitis were more likely to have reduced/absent numbers of goblet cells versus heathy 351 
dogs. Mansfield et al20 showed that decreased numbers of goblet cells were present in a cohort 352 
of Boxers with GC and observed an increase in goblet cells and improved histopathological 353 
abnormalities following eradication of invasive intra-mucosal Escherichia coli with enrofloxacin 354 
administration. Colonic goblet cell numbers in dogs with IBD of the present study were not 355 
reduced compared to the numbers of goblet cells in colonic biopsies obtained from healthy dogs. 356 
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As noted by Roth et al, however, changes in goblet cell numbers are not always accompanied by 357 
clinical signs since 28/48 samples from dogs with a clinical diagnosis of chronic diarrhea and/or 358 
colitis had histopathologic normal tissues (e.g., colitis grade of <2.0).26 359 
 There are some potential limitations to this study. We utilized a retrospective study design 360 
of archived gut specimens for diagnostic investigation from only 2 study centers. The healthy dog 361 
cohort was difficult to find at any one institution, hence this cohort was realized by pooling samples 362 
from laboratory reared animals from different (ISU and RVC) institutions. These dogs were younger 363 
than the majority of dogs with IBD but the availability of age and breed-matched control tissues for 364 
comparison to dogs with IBD was difficult due to the retrospective study design with limited 365 
availability of tissue blocks. It would have been ideal to study post-treatment biopsy samples from 366 
these same dogs with IBD to evaluate changes in disease activity and histopathology versus 367 
baseline values, but this was not possible in all cases. Lastly, endoscopic biopsy specimens from 368 
the stomach, duodenum, ileum, and colon were not available from all dogs for histopathologic 369 
interpretation and may have reduced the overall power of our study.   370 
 In conclusion, the simplified histopathologic scoring system provides objective and 371 
descriptive information on the extent of mucosal inflammation in the GI tract of dogs. This scoring 372 
system incorporates key WSAVA morphologic and inflammatory features which can now be 373 
applied to diagnostic interpretation of endoscopic specimens obtained from the stomach, 374 
duodenum, ileum, and colon. Compared to earlier grading schemes, the simplified scoring system 375 
shows improved utility in correlating histopathologic features (both summative histology scores 376 
and select histologic scores) to IBD clinical activity, at diagnosis, as defined by CIBDAI/CCECAI.  377 
We now provide a quantitative simplified scoring system for use by pathologists and clinicians 378 
alike in future studies (Table 5). Finally, gastric biopsies would appear to be less clinically useful 379 
versus duodenal and colonic biopsies for defining intestinal inflammation in dogs with IBD. 380 
 381 
 382 
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FIGURE LEGEND 554 
Figures 1-4. Inflammatory bowel disease, dog. Hematoxylin and eosin. Figure 1.  Stomach,  555 
  antrum. Within the lamina propria there is multifocal glandular atrophy and  556 
  replacement with mature fibrosis. Figure 2.  Duodenum. There is diffuse   557 
  moderate blunting and shortening (atrophy) of villus profiles. Figure 3.   558 
  Duodenum. Within the lamina propria there are markedly increased numbers of  559 
  neutrophils. Figure 4. Ileum. There is multifocal dilation of crypts. 560 
 561 
  562 
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Table 1. Parameters included in the simplified histopathologic scoring system for canine 563 
inflammatory bowel disease. 564 
 565 
*Quantity of lymphocytes/plasma cells, eosinophils, neutrophils, and/or macrophages as 566 
individual cellular infiltrates 567 
 568 
 569 
Table 2. Number of Tissues Sampled From Healthy Dogs and Dogs With Inflammatory Bowel 570 
Disease (IBD). 571 
 572 
GI Organ Stomach Duodenu
m 
Ileum Colon 
Healthy dogs (n=19) 
IBD dogs         
(n=42) 
7 
38 
5 
29 
9 
31 
10 
35 
 573 
 574 
 575 
Table 3. Correlations Between Organ-Specific Histopathologic Scores and Clinical Disease 576 
Activity in Dogs With Inflammatory Bowel Disease. 577 
Histopathologic Variable Correlation, (confidence interval 
[CI]) 
p-value 
Stomach - fibrosis r = 0.36, 95% CI = (0.07-0.59) 0.014 
Duodenum - LP lymphocytes r = 0.40, 95% CI = (0.07-0.02) 0.017 
Duodenum - LP neutrophils r = 0.45, 95% CI = (0.13-0.01) 0.007 
Duodenum - lacteal dilation r = 0.39, 95% CI = (0.06-0.65) 0.019 
Duodenum - villus stunting r = 0.40, 95% CI = (0.05-0.02) 0.024 
Ileum - crypt dilation r = 0.32, 95% CI = (0.01-0.57) 0.041 
Ileum - villus stunting r = 0.33, 95% CI = (0.02-0.58) 0.034 
Colon - fibrosis r = 0.47, 95% CI = (0.21-0.67) 0.001 
Colon - crypt dilation r = 0.42, 95% CI = (0.14-0.64) 0.003 
 578 
  579 
Location Histopathologic Parameter Grade  
Stomach (fundus or antrum) Fibrosis 
Intraepithelial lymphocytes 
Lamina propria infiltrates* 
Grade (0; normal, 1; mild, 
2; moderate and 3; marked) 
was assessed for each 
parameter according to the 
descriptors given in Table 
5.  
 
 
Duodenum Villus stunting 
Crypt dilation 
Lacteal dilation 
Surface epithelial injury 
Lamina propria infiltrates* 
Ileum As duodenum 
Colon Crypt dilation 
Fibrosis  
Goblet cell number 
Surface epithelial injury 
Lamina propria infiltrates* 
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Table 4. Agreement Among 8 Pathologists (κ Statistics) for Histopathologic Scoring of Lesions 580 
in Dogs With Inflammatory Bowel Disease.a 581 
 582 
Subscore Paramater Stomach Duodenum Ileum Colon 
Surface epithelium - 0.14 0.03 0.25 
Villus stunting - 0.33 0.09 - 
Crypt dilatation - 0.30 0 0.44 
Lacteal dilation - 0.36 0.10 - 
Colonic goblet cells - - - 0.40 
Mucosal fibrosis/atrophy 0.23 - - 0.16 
Intraepithelial lymphocytes 0.16 0.01 0 - 
LP lymphocytes and plasma cells 0.43 0.25 0.07 0.34 
LP eosinophils 0.42 0.46 0.09 0.54 
LP neutrophils - - 0 0.16 
LP macrophages 0 0.17 0 0.50 
Abbreviations: LP, lamina propria; -, not performed/not applicable 583 
aItalicized values denote a κ statistic of slight to fair agreement.  584 
 585 
Table 5. Correlations Between Organ-Specific Histopathologic Scores and Clinical Disease Activity in Dogs With Inflammatory Bowel Disease. 
Location  Histopathologic parameter Grade 
0 (Normal) 1 (Mild) 2 (Moderate) 3 (Marked) 
Stomach 
(fundus) 
Morphologic 
parameter 
Fibrosis (fibrocytes separating glands) ≤2 3-5  6-10  ≥11  
Inflammatory 
parameters 
Intraepithelial lymphocytes (lymphocytes per 
stretch 50 epithelial cells) 
≤2 3-10  11-20  ≥21 
Lamina propria lymphocytes and plasma cells 
(cells per x40 field) 
≤20 21-50  51-100  ≥101 
Lamina propria eosinophils (cells per x40 
field) 
≤2 3-20  21-50  ≥51 
Lamina propria neutrophils (cells per x40 
field) 
0   ≤20  21-50  ≥51 
Stomach 
(antrum) 
Morphologic 
parameter 
Fibrosis (fibrocytes separating gastric pits or 
mucous glands) 
≤10  11-15  16-20  ≥21  
Inflammatory 
parameters 
Intraepithelial lymphocytes (lymphocytes per 
stretch 50 epithelial cells) 
≤2 3-5  4-10  ≥11 
Lamina propria lymphocytes and plasma cells 
(cells per x40 field) 
 As fundus 
Lamina propria eosinophils (cells per x40 
field) 
≤2 3-10  11-50  ≥51 
Lamina propria neutrophils (cells per x40 
field) 
As fundus 
Duodenum 
and ileum 
Morphologic 
parameters 
Villous stunting (as % of normal length)*  100 75 50 <25 
Crypt dilation (% of crypts in a section dilated, 
distorted or contain eosinophilic 
material/degenerate neutrophils (‘crypt 
abscess’)) 
≤2  3-10  11-25  ≥26  
Lacteal dilation (as % of villous width) ≤25 26-50 51-75 ≥76 
Surface epithelial injury (% of villi per section) No erosion 
or ulceration 
≤10 erosion, 
no ulceration 
11-25 erosion 
and/or ≤10 
ulceration  
≥26 erosion 
and/or ≥11 
ulceration 
Inflammatory 
parameters 
Lamina propria lymphocytes and plasma cells 
(% area of one x40 villous field or cells 
between crypts) 
≤25, ≤2 26-50, 3-5 51-75, 6-10  ≥76, ≥11 
Lamina propria eosinophils (cells per x40 
field) 
≤3 4-10 11-20 ≥21 
Lamina propria neutrophils (cells per x40 
field) 
0 ≤10 11-30 ≥31 
Colon Morphologic 
parameters 
Crypt dilation and distension (% of crypts per 
section) 
0 ≤25 26-50 ≥51 
Fibrosis (fibrocytes separating crypts) ≤2 3-5  6-10  ≥11  
Goblet cell numbers (% reduction from 
normal) 
0 ≤25 26-50 ≥51 
Surface epithelial injury (% of villi per section) As duodenum and ileum 
Inflammatory 
parameters 
Lamina propria lymphocytes and plasma cells 
(cells between crypts) 
≤5 6-10 11-20 ≥21 
Lamina propria eosinophils (cells per x40 
field) 
≤2 3-10 11-20 ≥21 
Lamina propria neutrophils (cells per x40 
field) 
As duodenum and ileum 
Lamina propria macrophages (cells per x40 
field) 
≤2 3-20 21-50 ≥51 
 N.B. accurate assessment only possible with well-oriented endoscopic samples 
